americanpharmaceuticalreviewMarch 09, 2020
Tag: Annovis , Parkinson , Dementia , ANVS401
Annovis Bio was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401. The Company expects multiple patents to be generated from this patent family, each targeting specific neurodegenerative diseases independently.
"Based on discussions with the patent office, we have filed additional patent applications for each individual neurodegenerative disease that our drug targets. We plan to provide further updates as we execute on this process," Maria Maccecchini, Ph.D., CEO of Annovis, said.
ANVS401 improves axonal transport, the information highway of the nerve cell, by attacking multiple neurotoxic proteins simultaneously. ANVS401 is the lead compound in the Company’s ongoing Phase 2a clinical trial for Alzheimer’s disease and in a planned Phase 2a trial for Parkinson’s disease.
The Company is planning a 50-patient Phase 2a study in Parkinson’s disease with primary endpoints targeting a decrease in neurotoxic protein levels, increase in neurotransmitters and neurotrophic factors, lowering of inflammatory proteins, lowering of neurodegeneration markers, and positive cognitive and functional outcomes.
"We believe we have a novel solution to stop the course of Parkinson’s disease and Alzheimer’s disease, areas of unmet need valued in the multibillions of dollars and growing," said Dr. Maccecchini. "The successful completion of our two Phase 2a studies will provide optimal information on target and pathway engagement in both diseases and allow us to move into pivotal studies."
Parkinson’s disease affects an estimated one million people in the U.S. and as many as 10 million globally. An estimated 5.8 million people in the U.S. have Alzheimer’s disease and there are approximately 44 million people worldwide living with the disease.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: